CB2 Insights (CSE:CBII) (OTCMKTS:CBIIF), the medical cannabis data group, revealed it had increased its market presence in the UK, saying it will license its technology to MyAccess Clinics (MAC) to manage their patient data.
The latter operates multiple clinics in the UK and is focused on providing care for patients with unmet needs, which licensed medicines have failed to address.
It has chosen CB2 Insights’ Electronic Data Capture (EDC) software to manage the complex and layered world of patient data in its growing clinic base.
"The UK market continues to blossom at a rapid pace, and we are proud that our research and data technology assets continue to be sought to expedite growth in the market,” said Prad Sekar, the CEO at CB2 Insights.
"MyAccess Clinics has an exceptional and comprehensive vision for its development in the UK’s medical cannabis market and we are excited to be a part of that effort."
The EDC software has been used throughout the US and Canada and is purpose-built for medical cannabis operations.
"As a company, we are proud to be one of the first to service the emerging UK medical cannabis market," said Graham Woodward, MyAccess Clinics' clinical director.
"CB2 Insights’ software will play an integral part in the administration of our clinics and will increase our ability to manage data, thereby improving our patient care.”
It comes after in July this year, CB2 Insights was selected as the exclusive research technology platform for UK-based Drug Science and its medical cannabis pilot program, involving 20,000 patients.
Shares surged 7.7% to C$0.14 in Toronto.
Contact the author at [email protected]nvestors.com